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inhibits hepatic stellate cell activation
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Abstract
Background: Hepatic fibrosis is a dynamic process which ultimately leads to cirrhosis in almost patients with
chronic hepatic injury. However, progressive fibrosis is a reversible scarring response. Activation of hepatic stellate
cells (HSCs) is the prevailing process during hepatic fibrosis. Osthole is an active component majorly contained in
the fruit of Cnidium monnieri (L.) Cusson. This present study investigated the therapeutic effects of osthole on rat
liver fibrosis and HSC activation.
Results: We established the thioacetamide (TAA)-model of Sprague–Dawley (SD) rats to induce hepatic fibrosis.
Rats were divided into three groups: control, TAA, and TAA + osthole (10 mg/kg). In vivo, osthole significantly
reduced liver injury by diminishing levels of plasma AST and ALT, improving histological architecture, decreasing
collagen and α-SMA accumulation, and improving hepatic fibrosis scores. Additionally, osthole reduced the
expression of fibrosis-related genes significantly. Osthole also suppressed the production of fibrosis-related
cytokines and chemokines. Moreover, nuclear translocation of p65 was significantly suppressed in osthole-treated
liver. Osthole also ameliorated TAA-induced injury through reducing cellular oxidation. Osthole showed inhibitory
effects in inflammation-related genes and chemokines production as well. In vitro, we assessed osthole effects in
activated HSCs (HSC-T6 and LX-2). Osthole attenuated TGF-β1-induced migration and invasion in HSCs.
Furthermore, osthole decreased TNF-α-triggered NF-κB activities significantly. Besides, osthole alleviated TGF-β1- or
ET-1-induced HSCs contractility.
Conclusions: Our study demonstrated that osthole improved TAA-caused liver injury, fibrogenesis and
inflammation in rats. In addition, osthole suppressed HSCs activation in vitro significantly.
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Background
Hepatic fibrosis is a dynamic wound-healing response to
chronic hepatic injuries such as alcoholism and viral hepa-
titis in patients. Accumulated evidence suggests that hep-
atic fibrosis is a reversible process [1]. Activation of hepatic
stellate cells (HSCs) is the prevailing process during hepatic
fibrosis [2]. Activated HSCs generate fibrosis by accumulat-
ing extracellular matrix (ECM), secreting cytokines and
chemokines, and enhancing the ability of chemotaxis [3].
Refraining quiescent HSCs from transformation is a crucial
approach to impeding the fibrotic response in the liver.
Activated HSCs undergo phenotypic transformation
with diverse functional changes, including fibrogenesis,
chemotaxis, contractility, proliferation, cytokine secre-
tion, and ECM degradation [4]. HSCs could be triggered
to transdifferentiate from quiescent into activated form
by inflammatory mediators or growth factors, such as
tumor necrosis factor-α (TNF-α), tumor growth factor-
β1 (TGF-β1) and endothelin-1 (ET-1) [5–7].
Osthole (C15H16O3, MW=244.29) is an active compo-
nent present in many medicinal plants especially in the fruit
of Cnidium monnieri (L.) Cusson, which has long been
used in clinics with pharmacological properties, such as
anti-oxidation and anti-inflammation [8]. Many reports in-
dicated that osthole improves hepatic steatosis, including
reducing triglyceride synthesis [9, 10], hepatic inflammation
[11] and modulating lipogenic gene expressions in the liver
[12]. Evidence has shown that osthole also suppresses the
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in vitro secretion of hepatitis B surface antigen in a hepa-
toma cell line [13]. However, its anti-fibrotic effect in the
liver still requires further investigation.
Thioacetamide (TAA, CH3CSNH2) administration is a
well-accepted method to establish liver fibrosis in rats
[14, 15]. TAA leads to hepatotoxicity by oxidation pro-
cesses. The metabolites from TAA are more toxic than
TAA and can result in the liver injury. Studies indicated
that the pathology of TAA-induced liver injury is similar
in some ways to that of cirrhosis in human [16].
In the present study, we investigated both the in vivo
and in vitro effects of osthole in hepatic fibrotic rats in-
duced by TAA, and HSCs activated by TNF-α, TGF-β1,
or ET-1.
Methods
Drug preparation and chemicals
For in vivo, osthole (Selleck Chemicals, Boston, MA, USA,
Additional file 1: Figure S1) was mixed with 0.7 % carb-
oxyl methyl cellulose (CMC, Sigma-Aldrich, St. Louis,
MO, USA) for administration. For in vitro, osthole was
dissolved in DMSO and diluted with medium to give a
DMSO concentration below 0.1 %. TGF-β1 (1 ng/ml),
TNF-α (10 ng/ml) and ET-1 (1 nM, Sigma-Aldrich) were
used for stimulation.
Animal and experimental model of fibrosis
A total of 28 male SD-strain rats (8-week-old, National
Yang-Ming University Experimental Animal Center) were
housed with free access to food and water in an air-
conditioned room at 21 °C with 12 h light–dark cycle.
Hepatic fibrosis was induced by TAA (Sigma-Aldrich) dis-
solved in normal saline and injected intraperitoneally (i.p.)
into rats twice a week at a dosage of 250 mg/kg for 6 weeks.
At the beginning of week three, rats were randomly divided
into three groups: (a) Control group: rats given saline injec-
tions and gavage of 0.7 % CMC (n = 8); (b) TAA group: rats
given TAA injections and gavage of 0.7 % CMC (n = 10), (c)
TAA+ osthole group: osthole (10 mg/kg) was given by gav-
age twice daily for 4 weeks (n =10). Each rat was anesthe-
tized by pentobarbital (50 mg/kg i.p.), then the whole liver
was removed for measurements. Left-lobe sections were
used for immunohistochemical studies by fixation (10 %
formalin) and subsequent paraffin-embedment. Other liver
tissues were used for isolating proteins and RNA. All ani-
mal studies were approved by the Animal Experiment
Committee of the University (IACUC No: 98-111) and con-
ducted humanely, in accordance with the Guide for the
Care and Use of Laboratory Animals (National Academic
Press, USA, 1996).
Measurement of hepatic injury
Rat blood samples were obtained by heart puncture
after anaesthesia. Plasma was separated and utilized for
measuring alanine transaminase (ALT) and aspartate
transaminase (AST) activities as markers of liver injury
using a colorimetric analyzer (Dri-Chem 3000; Fuji Photo
Film Co., Tokyo, Japan), as described previously [17].
Histological examination and immunohistochemistry
Paraffin-embedded liver sections were deparaffinized
and dehydrated in a graded alcohol series. Sections
were stained with GM's Hematoxylin-eosin (H&E) dye
(Muto Pure Chemicals Co. Ltd, Tokyo, Japan) or
Picrosirius red kit (Polysciences, Inc., Warrington, PA,
US) to evaluate inflammatory degree and collagen dis-
tribution, respectively. Immunohistochemical staining
to detect α-SMA was performed by using the DAKO
EnVision System (DAKO North America, Carpinteria,
CA, USA) according to the manufacturer’s protocol.
The degree of hepatic fibrosis was evaluated using
Ishak fibrosis scoreby a pathologist (YC Chiu) in a
blind fashion [18].
Quantitative quantitative reverse transcription-
polymerase chain reaction (qRT-PCR) analysis
Hepatic RNA was extracted by TRIzol® Reagent (Life
Technologies, Carlsbad, CA, USA) according to the
manufacture protocol, as previously reported by us [19].
RNA was reverse-transcribed into cDNA using oligo-dT
and dNTP. PCR was performed by the StepOnePlus™
Quantitative Real-Time PCR System (Life Technologies),
according to the manufacturer’s instructions. The se-
quences of primers for PCR are listed as supporting in-
formation (Additional file 2: Table S1).
ELISA for cytokines
Rat plasma was used to determine the levels of cyto-
kines and chemokines, including tissue inhibitor of
metallopeptidase-1 (TIMP-1), intercellular adhesion
molecule-1 (ICAM-1), CXCL7, CD62L, VEGF, CX3CL1,
LIX, CXCL1, CCL20, and CCL5, using an Rat Cytokine
Array Kit (R&D Systems, Minneapolis, MN, USA), ac-
cording to the manufacturer’s specifications.
Western blotting analysis
Liver protein extracts were harvested with RIPA buffer.
Nuclear extracts were prepared according to our previous
study [19]. Cell lysates were separated with SDS-PAGE
and transferred onto PVDF. The following antibodies have
been used in various dilutions: anti-α-SMA (Calbiochem-
Novabiochem, San Diego, CA, USA), and anti-α-tubulin,
anti-Nrf-2, anti-p65, anti-JunD (Santa Cruz Biochnology,
Santa Cruz, California, CA, USA), and anti-PCNA (Cell
Signaling Technology, Danvers, MA, USA). The HRP-
conjugated secondary antibodies were used and blots were
developed using ECL detection reagent and detection im-
aging system.
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Glutathione (GSH), 4-hydroxynonenal (4-HNE), and
malondialdehyde (MDA) in liver tissue
Liver tissue samples (0.05 g) were washed with ice-cold 1X
PBS containing heparin (0.16 mg/ml). Oxidized glutathione
(GSSG) and total GSH were measured using Glutathione
assay (Trevigen, Gaithersburg, MD, USA). For total
GSH assay, liver tissue samples were mixed with ice-
cold 5 % (w/v) metaphosphoric acid (Sigma-Aldrich)
for homogenization, and then centrifuged at 12,000 g
for 15 min at 4 °C. After serially diluting samples, we
mixed prepared samples, 1X Assay Buffer, and 4 μM
GSSG in 96-well plates. Reaction Mix (150-μl) was
added to each well, and then the absorbance in the
wells was tested at 405 nm using Sunrise ELISA
Reader (TECAN, Männedorf, Switzerland). For oxi-
dized GSH assay, prepared samples were mixed with
4-vinylpyridine (2 M, Sigma-Aldrich) and 4-μM GSSG.
After incubating in a 96-well plate for 1 h at room
temperature, we followed the protocols to measure
total GSH.
Liver tissue samples (0.05 g) were homogenized with
ice-cold 1X PBS containing heparin (0.16 mg/ml). The
homogenates were centrifuged at 1500 g for 15 min at
4 °C. 4-HNE and MDA levels were measured using 4-
HNE ELISA kit and MDA ELISA kit (MyBioSource, San
Diego, CA, USA), according to manufacturer's instruc-
tions. The absorbance in the wells was measured at
450 nm using Sunrise ELISA Reader.
Cell culture
The HSC-T6 and LX-2 cells were both generous gifts from
Prof. S.L. Friedman (Mount Sinai Medical School, USA),
the former being an immortalized cell line of rat HSCs and
the latter, immortalized human HSCs. HSC-T6 and LX-2
cells were incubated in DMEM (Corning, Tewksbury, MA,
USA) containing separately 10 % and 2 % fetal bovine
serum (FBS, pH 7.0; Gibco BRL, Gaithersburg, MD, USA)
at 37 °C in 5 % CO2.
Wound-healing assay
HSCs were seeded in culture inserts (ibidi, Martinsried,
Germany) on collagen coated 24-well plates. After 24-h
serum starvation, cells with cell-free zone were pre-
treated with osthole (1, 3 and 10 μg/ml) for 1 h, then in-
cubated with TGF-β1 for 24 h. HSCs migration was
quantified by the area of cells in the cell-free zone, as
previously reported by us [19].
Trans-well invasion assay
Serum-starved HSCs were cultured on chemotaxis
chamber Millicell® (Merck Millipore) with 8-μM pores,
which were pre-coated with Matrigel™ Matrix (BD Bio-
sciences, San Jose, CA, USA). The bottom wells were
containing serum-free medium and TGF-β1 plus osthole
(1, 3 and 10 μg/ml). The cells and chambers were incu-
bated at 37 °C for 24 h. Cells migrated to the lower sur-
face were stained with hematoxylin to define the cell
nuclei, as previously reported by us [19].
Luciferase assay
HSCs were transfected with Fugene-6 (Roche, Basel,
Switzerland). NFκB-Luc reporter construct (1 μg/well)
(Stratagene, La Jolla, CA, USA) was added to cells with
plasmid CMV-β-galactosidase (CMV-β-gal, 0.2 μg/well;
Promega, Madison, WI, USA). CMV-β-gal served as an
internal control to normalize the transfection efficiency.
After osthole (1, 3 and 10 μg/ml) treatment for 1 h,
NF-κB activity was stimulated by TNF-α for 6 h. Cell
lysates and luciferin (Promega) were detected by a
luminometer-VICTOR2 Multilabel Counter (Perkin
Elmer Inc., Waltham, MA, USA), as previously re-
ported by us [19].
Contraction assay
The protocol was modified from a previously published
method [20]. In brief, the cells were mixed with 1-M
NaOH, 10X Hank’s buffer, inducers ET-1 or TGF-β1,
and type I collagen. Collagen gels were treated for 48 h
with osthole (10 μg/ml) and the area of each gel was
compared.
Statistical analysis
The data are expressed as mean ± standard deviation.
One-way analysis of variance (ANOVA, under the
Tukey’s test) was used for comparison of molecular and
biochemical parameters. A non-parametric method (the
Dunn procedure under the Kruskal-Wallis test) was used
for multiple pairwise comparisons between groups for
the histological grades of fibrosis. The statistical signifi-
cance test was done by Scheffe’s test to confirm where
the differences occurred between groups. Software SPSS
was used for statistic analysis. A significant difference
was considered at p < 0.05.
Results
Osthole protected the rat liver against TAA-stimulated
injury
To identify the therapeutic effect of osthole in TAA rats,
we first observed the liver condition of each group. In
macroscopic views, control livers showed smooth surface
and brown color, but TAA-group livers displayed pink and
numerous irregular nodules. Livers from TAA+ osthole
rats exhibited normally dark red color without surface
nodularity (Fig. 1a). The mortality among three groups was
not significantly different (Additional file 3: Figure S2). We
further assessed the effect of osthole treatment on liver in-
jury by biochemical analyses of plasma enzymes. TAA-
injected rats showed significantly higher ALT and AST
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activities than control rats, suggesting hepatic injury due
to TAA. Results also showed that the group had lower
levels of ALT and AST than the TAA group (Fig. 1b).
There was no renal impairment according to the value of
creatinine in all groups (data none shown). The body
weight of TAA-treated rats was significantly lighter than
that of control rats, and there was no difference in body
weight between TAA-treated rats with and without ost-
hole treatment (Additional file 4: Figure S3). There was no
difference in liver weight between control and TAA rats.
However, TAA + osthole-treated rats showed a significant
decrease in liver weight compared with TAA rats (Fig. 1c),
suggesting that osthole treatment diminished hepatic in-
jury in TAA rats.
Osthole attenuated TAA-induced rat liver fibrosis
The function of osthole on TAA-induced hepatic injury
and fibrosis were then evaluated based on the represen-
tative H&E- and Picrosirius red-stained liver sections.
We observed changes in histological examination of
livers from TAA rats compared with control rats, such
as damage of hepatocytes and progressive increase and
expansion of fibrous septa. Histological analysis re-
vealed the suppressive effects of osthole in TAA-
induced hepatic injury and fibrosis (Fig. 2a). Picrosirius
red stain showed collagen fibres deposited in TAA-
treated livers significantly compared with control rats
(Fig. 2b). In addition, decreased α-SMA-positive cells were
found in the fibrous septa portal tracts and sinusoids of
the TAA + osthole-treated livers by immunohistochemical
staining compared with TAA-treated livers (Fig. 2c). Con-
sistently, the fibrosis score in TAA rats (0.72 ± 0.10) was
significantly higher than that in control rats (0.14 ± 0.09),
and osthole treatment (0.21 ± 0.14) significantly amelio-
rated hepatic fibrosis in TAA rats (Fig. 2d). The results
showed that TAA intoxication led to a significant increase
of collagen-positive area in the rat liver, which was attenu-
ated by osthole treatment (Fig. 2e). We further confirmed
that osthole treatment significantly attenuated TAA-
induced α-SMA protein expression by Western blotting
analysis (Fig. 2f). TAA-induced fibrosis-related gene ex-
pression, such as α-sma and procollagen I, was significantly
reduced by osthole administration. There were also obvi-
ous decreases of mRNA levels in ECM synthesis-related
genes, including icam-1, mmp2, mmp9 and mmp13
(Fig. 2g). To investigate whether osthole treatment affects
the secretion of TAA-induced ECM-related cytokines and
chemokines, we measured the production of distinct
ECM-formation mediators by cytokine array. Results illus-
trated that osthole treatment exhibited a significant reduc-
tion of ICAM-1, CD62L, VEGF, and CX3CL1 levels.
TIMP-1 and CXCL7 levels in the TAA+ osthole group
tended to be lower than those in the TAA group, but did
not reach statistic significance (Fig. 2h). The data suggested
that osthole treatment alleviated TAA-caused liver fibrosis
and ECM synthesis.
Fig. 1 General profiles in control rats and TAA-induced fibrotic rats with or without osthole treatment. a Rat liver images from three groups: control rats
were given only CMC (n= 8); and TAA-group rats were given CMC with TAA injection (n= 10); TAA + osthole-group rats were gavage osthole (10 mg/kg)
in CMC with TAA injection (n= 10). The protocol of treatment was described in the Methods. Scale bar represents 1 cm for livers. b Plasma levels of ALT
and AST from all groups. c Liver weight was recorded after sacrifice. Data are shown as mean ± SD of 8 rats in each group.*p< 0.05; **p< 0.01, compared
with other groups
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Osthole suppressed TAA-induced oxidation and
inflammation in rat liver
In chronic liver diseases, inflammation is a major feature
associated with fibrogenesis [21, 22]. We postulated that
osthole treatment might attenuate TAA-induced injury by
inhibiting liver inflammation. The H&E-stained liver sec-
tions in TAA injected rats showed portal triad inflamma-
tion and periportal inflammatory cell infiltration (Fig. 2a).
We further prepared nuclear fractions to determine trans-
location of p65 and JunD. The p65 is the main subunit of
NF-κB which can be triggered to translocate into the
nucleus then activating transcription of various genes. JunD
is a functional component of the activator protein-1 (AP-1)
transcription factor complex known to activate AP-1-
mediated transcription of genes in inflammatory response
[23]. Data of nuclear fraction using Western blotting
analysis indicated that there were more p65 and JunD
nuclear translocation in TAA-injected livers than in the
control group. Osthole treatment evidently reduced p65
translocation into nuclei in TAA-injected rats (Fig. 3a). The
JunD translocation in osthole-treatment group tended to be
lower than those in the TAA group. Nrf-2 plays a critical
role in stress-inducible genes and also in cellular resistance
to oxidants. TAA-promoted Nrf-2 translocation was
profoundly down-regulated by osthole treatment, suggest-
ing that oxidative stress in the liver might be counteracted
by osthole (Fig. 3a). In Glutathione assay, we measured the
levels of total GSH and oxidized GSSG, and then
Fig. 2 Osthole attenuated liver injury and fibrogenesis in the TAA rat model. Representative liver sections were obtained from groups as follows:
control, TAA and osthole-treated TAA rats. Liver sections were analyzed with a H&E-, b Picrosirius red- and c immunostaining of α-SMA. d Fibrosis
scores were assessed by a pathologist in a blind fashion. e Quantification of collagen-positive area was performed using Metamorph software.
f α-SMA protein in liver tissues detected by Western blotting analysis. g The expressions of α-sma and procollagen I, icam-1, mmp2, mmp9 and mmp13
transcripts in livers measured by qRT-PCR. h ELISA of TIMP-1, ICAM-1, CXCL7, CD62L, VEGF, and CX3CL1 in plasma of various groups. Data are shown as
mean ± SD of 8 rats in each group. *p < 0.05; **p < 0.01, compared with other groups
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determined the level of GSH/GSSG ratio. The results
showed that TAA treatment led to higher GSH/GSSG ratio,
and osthole treatment restored GSH depletion in the liver
(Fig. 3b). In addition, we found that osthole reduced the
amount of TAA-caused lipid peroxidative products 4-HNE
and MDA in the liver (Fig. 3c, d). To further explore the
anti-inflammatory role of osthole treatment, the mRNA
levels of interleukin-1β, tnf-α and inos genes in the rat liver
were evaluated by qRT-PCR. The expression levels of these
inflammation-related genes in the liver were increased in
TAA-injected rats, which were obviously attenuated by
osthole treatment (Fig. 3e). Additionally, levels of
inflammation-related chemokines in the TAA group were
significantly higher than those in control rats, but only
CXCL1 levels showed significant reduction after osthole
treatment. LIX and CCL20 levels in the TAA+ osthole
group tended to be lower than those in the TAA group, but
did not reach statistic significance (Fig. 3f).
Fig. 3 Osthole suppressed inflammation and oxidation in TAA-injected rat liver. a Nuclear fractions of rat liver from different treatment groups
were analyzed by Western blotting analysis. For expression of p65, JunD and Nrf-2, PCNA expression served as loading control in nuclear protein.
b GSH/GSSG ratio in the livers was measured by Glutathione kit. c Levels of 4-HNE in the livers were measured using 4-HNE ELISA kit. d Levels of
MDA in the livers were measured using MDA ELISA kit e qRT-PCR showed the expressions of interleukin-1β, tnf-α and inos transcripts in rats. f
ELISA of LIX, CXCL1, CCL20 and CCL5 in plasma. Data are shown as mean ± SD of 6 rats in each group. *p < 0.05; **p < 0.01, compared with
other groups
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Osthole downregulated chemotaxis and contraction of
activated HSCs
The in vivo results above suggested that osthole could
suppress TAA-caused hepatic fibrogenesis and inflamma-
tion in rats. HSCs play an important role during hepatic
fibrogenesis, and HSC activation is also crucially related to
hepatic inflammation. Osthole (1, 3, and 10 μg/ml) showed
no cytotoxicity to HSC-T6 and LX-2 cells after 24 h treat-
ment (Additional file 5: Figure S4). We utilized HSC-T6
and LX-2 to determine whether osthole could inhibit
HSC activation induced by chemotactic stimulation. Using
wound-healing assays, the inhibitory effect of osthole on
TGF-β1-induced HSC migration were revealed. After 24 h
exposure to TGF-β1, HSCs (both HSC-T6 and LX-2)
showed obvious migration to the cell-free zone. Moreover,
osthole (10 μg/ml) inhibited TGF-β1-induced migration in
HSCs significantly (Fig. 4a). We also performed trans-well
invasion assay to assess the ability of cell invasion. Osthole
(1-10 μg/ml) curbed HSC invasion in response to TGF-β1.
The cell number of TGF-β1-stimulated HSCs was higher
than that in the control group, whereas osthole treatment
(3, 10 μg/ml) decreased TGF-β1-stimulated invasion signifi-
cantly in both HSC cell lines (Fig. 4b). Furthermore, we
used the luciferase assay to determine NF-κB activity, which
is a hallmark of HSC activation. In both HSC cell lines,
osthole (3, 10 μg/ml) led to a marked inhibition of TNF-α-
induced NF-κB luciferase activity (Fig. 4c). HSC activation
exhibits many features, the most prevailing of which
includes tissue contraction mediated by contractile myofi-
broblasts. Therefore, we measured HSC contractility by
ET-1 and TGF-β1 stimulation, both well known to induce
HSC contraction in the liver. We treated HSCs plated on
collagen lattices with osthole (10 μg/ml) and ET-1 or TGF-
β1 for 48 h. Osthole significantly reduced both ET-1- and
TGF-β1-promoted HSC contraction (Fig. 4d). We substan-
tiated our hypothesis that osthole was capable of interrupt-
ing HSC activation in HSC-T6 and LX-2 cells.
Discussion
In the present study, we demonstrated that osthole showed
anti-hepato-fibrotic effects on TAA-caused injured livers
with attenuating (a) hepatic fibrosis score and collagen
deposition, (b) hepatic α-SMA protein accumulation, (c)
hepatic mRNA expressions of α-sma, procollagen I, icam-1,
mmp2, mmp9 and mmp13, (d) hepatic translocation of
p65, JunD, and Nrf-2 proteins, (e) plasma levels of ALT and
AST, (f) plasma levels of several inflammation- and
fibrosis-related cytokines and chemokines. In our further
in vitro study of HSCs, osthole exhibited suppressive effects
on HSC activation, such as inhibiting TGF-β1-induced
migration and invasion, TNF-α-stimulated NF-κB activity,
and TGF-β1- or ET-1-stimulated contractility. Overall, the
pure compound osthole from Cnidium monnieri (L.)
Cusson significantly suppressed hepatic fibrosis in TAA-
injected rats, and inhibited HSCs activation, which is the
key event associated with hepatic fibrosis.
TAA causes toxicity in hepatocytes and then induces
acute and chronic liver injury through free radical and
oxidative stress [24]. The first step of TAA metabolism is
through flavin-adenin dimucleotide (FAD)-containing
monooxygenase (FMO) system in mammals [25]. Next, the
resulting TAA metabolites would be converted to TAA-S-
dioxide by cytochrome P450 monoxygenases [26]. TAA-S-
dioxide could covalently bind to the molecules in the liver
and trigger oxidative stress to cells [27, 28]. The serial
events would eventually lead to liver necrosis. Previous
studies indicated that the mechanism of TAA-caused liver
injury involves the induction of the oxidative stress in mul-
tiple cell types. Researchers have found that both catalase
and glutathinone peroxidase can reduce the TAA-induced
free radical production [24, 29]. The depletion of the anti-
oxidant GSH is one of the indices of oxidative stress. High
reduced GSH levels are associated with increased oxidative
damage by free radicals in the TAA-group. GSH reductase
converts GSSG to reduced GSH. We have found that
osthole restored the levels of GSH/GSSG. Moreover, the
peroxidative products 4-HNE and MDA induced by TAA-
injection were both decreased by osthole treatment signifi-
cantly. These results indicated that osthole ameliorated
TAA-induced injury through reducing cellular oxidation.
We used 10 μg/ml as the maximum concentration of
osthole in preliminary in vitro assays. Therefore, we
estimated that around 10 mg⁄kg is needed in vivo as a dose
of osthole, and we also used 10 μg/ml to investigate more
suppressive effects of osthole in HSC activation in present
in vitro assays. In addition, we referenced study which
utilized 10 mg⁄kg (i.v.) in rats for pharmacokinetics experi-
ments [30]. Although our gavage method might result in
lower bioactivity, present results showed that osthole at
10 mg⁄kg could improve TAA-caused hepatic fibrosis and
inflammation in rats.
Osthole attenuated hepatic fibrosis scores and accumula-
tion of α-SMA protein and collagen, together with plasma
levels of ALT and AST in TAA-injected rats. However, it
did not improve body weight loss. These consequences
suggested that there might be only partial amelioration with
osthole treatment of pathological state in TAA-caused
lesion. Osthole is an active constituent of Chinese
medicine-Cnidium monnier (L.) Cusson [31], which has
been used clinically in traditional prescriptions such as “She
Chuang Zi” for anti-allergic action [32], androgenic action
[33]. anti-inflammation [34] and anti-apoptosis [35]. Mod-
ern reports have shown that osthole possesses therapeutic
function in various diseases, such as alleviating skin inflam-
mation [36], protecting lung [37] and kidney injuries [38],
anti-diabetic [39, 40] and anti-osteoporosis [41]. In the
hepatic field, osthole has been shown to inhibit the secre-
tion of HBV surface antigens in vitro [13] and shown to
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prevent HCC cells growth [42, 43]. There were several
studies focused on the function of osthole in liver steatosis
[9, 10, 44], but few discussion about its efficacy in hepatic
fibrosis. We demonstrated that osthole did ameliorate
hepatic inflammation and fibrogenesis in TAA-model.
NF-κB is a major ubiquitous transcription factor regu-
lating the expression of genes involved in inflammatory
responses. Sensitizing NF-κB signaling via activation of
IκB-kinase (IKK) complex and degradation of IκBα pro-
tein, in turn, releases the cytosolic heterodimer p65/p50,
and then p65 translocates into nucleus to activate tran-
scription of various genes. Previous studies mentioned
that osthole suppresses the activity and protein expression
of NF-κB [11, 42]. Our findings also indicated osthole
inhibited p65 translocation in vivo, and blunted in vitro
NF-κB activity in HSCs. JunD is the member of the JUN
family associated with proinflammatory transcription
factor AP-1 [45] and it is important for cytokine-induced
liver damage [46]. Although there is no evidence about
the cell-specific function of JunD, we could find positive
relevant between p65 and JunD in osthole-attenuated
TAA-caused liver damage. Our data showed that TAA
injections induced Nrf-2 translocation in injured liver, and
osthole treatment ameliorated this phenomenon. There
was a study showing that deletion of Nrf-2 may abolish
liver injury [47]. Alternatively, osthole has potential to
reduce cellular oxidation and hence oxidation-induced
Nfr-2 activation is reduced (Fig. 3a), which may counteract
Nrf-2-induced responses. Evidence has shown that osthole
induces gene expressions of proinflammatory cytokines
such as TNF-α and IL-2 [48]. Moreover, osthole inhibits
TNF-α production and showed anti-oxidative ability in
alcohol-induced fatty liver in mice [10]. In our study, we
found that osthole treatment downregulated TAA-induced
mRNA levels of tnf-α, interleukin-1β, and inos. Reports
have shown CXCL1 is genetic risk factors involved in the
pathogenesis of NASH and alcoholic cirrhosis, and CXCL1
is a ligand for CXC chemokine receptor family expressed
on HSCs [49, 50]. In our cytokine assay, results showed that
production of CXCL1 was reduced in osthole-treated TAA-
rats. Our data indicated that osthole exerted inhibitory
effects on inflammatory responses in hepatic fibrosis.
Inflammation and HSC activation could be considered
as two distinct mechanisms in fibrogenesis. However, both
processes affect each other in several ways [2, 3]. When
the liver is injured by multiple threatening, the damaged
liver tissue is surrounded by myofibroblasts and inflam-
matory cells. In our present study, results indicated that
osthole decreased the infiltration of multiple cell types in
the rat liver (Fig. 2a). It was reported previously that at the
early stage of liver injury, infiltrated inflammatory cells
around injured sites can secret cytokines and chemokines
to induce HSCs activation [51]. In this study, we observed
that osthole reduced the hepatic production of α-SMA,
inflammatory cytokines and chemokines in TAA-treated
rats. Our in vitro results also indicated that osthole inhib-
ited both TNF-α-induced NF-κB activity and TGF-β-
induced α-SMA in HSCs. Therefore, in vivo and in vitro
results demonstrated that osthole inhibited both HSC
activation and inflammation in rat livers.
Chemotaxis is one of features in activated HSCs, and
this action in normal physiology serves to repair injured
tissues. Whereas, moving HSCs keep secreting inflamma-
tory mediators and producing ECM once the liver
starts unhalted fibrogenic processes. We performed two
methods to confirm that osthole inhibited TGF-β1-
induced wound-healing chemotaxis and invasion of HSCs.
There was a report showing the inhibitory function of
osthole in migration and invasion of breast cancer cells
[52]. Chemokine secretion has been known for inducing
cell migration [53]. In our in vivo study, we found osthole
treatment reduced chemotaxis-related cytokines. Cell
contractility is a major characteristic of HSC activation as
well. Activated HSCs contribute to increased portal pres-
sure during progression from hepatic fibrosis to cirrhosis
and HSCs are reported as a main target for ET-1 action in
liver [54]. Briefly, ET-1 promotes HSCs to show higher
contractility and then increases portal venous pressure.
HSC activation mainly requires TGF-β1 which provokes
diverse inflammatory and fibrogenic responses [55]. To
our knowledge, there has been no scientific report on
whether osthole can affect HSC contractility, and our
current results show that osthole suppressed TGF-β1- or
ET-1-stimulated HSC contraction.
(See figure on previous page.)
Fig. 4 Osthole downregulated HSC activation. a Wound healing assay in HSCs (both HSC-T6 and LX2 cells). Cells were treated by osthole (1, 3 and
10 μg/ml) after creating wounds. Graphs represent cell migration assessed at 0 h and 24 h after exposure to TGF-β1 (1 ng/ml), and quantification of
wound closure was shown below, n = 3. b Cell invasion assay in HSCs. Cells were treated by osthole (1, 3 and 10 μg/ml) and then stimulated with
TGF-β1 for 24 h. Graphs displaying the bottom side of the filter inserts with cells that migrated through the filter pores. Graphs of quantification graphs
represent the analysis of the cell count. c NF-κB activity of HSCs which were transfected with CMV-βgal and the reporter plasmid containing NF-κB
responsive region for 24 h. Cells were pre-treated with osthole (1, 3 and 10 μg/ml) for 1 h, followed by 6 h TNF-α (1 ng/ml) stimulation, then NF-κB
activity was detected by luminescence. CMV-βgal was used as internal control to normalize the transfection efficiency. n = 3. d Osthole-inhibited
ET-1- or TGF-β1-induced HSC contraction. Cultured HSCs were serum-starved 24 h prior to seeding onto collagen lattices. Cells were pre-treated with
control or osthole in 10 μg/ml and subsequently treated with ET-1 (1 nmol/l) or TGF-β1(1 ng/ml) after 30 min. Graphs of quantification graphs
represent the analysis of the area of collagen circle. n = 3. *p < 0.05; **p < 0.01, compared with other groups
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Conclusion
Osthole could be considered as a potential therapeutic
agent in view of our current pharmacological results. In
conclusion, our results demonstrated that osthole ame-
liorated TAA-injected liver injury and fibrogenesis in
rats, possibly through inhibiting HSC activation.
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